Dunsire Takes XTuit Helm As First Targets Approach The Clinic
The privately-held biopharma, focused on fibrotic diseases and cancer, appointed oncology veteran Deborah Dunsire as president and CEO as the firm’s first drug candidates mature toward the clinic.
You may also be interested in...
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.